Aligning the Economic Value of Companion Diagnostics and Stratified Medicines

被引:5
作者
Blair, Edward D. [1 ]
Stratton, Elyse K. [1 ]
Kaufmann, Martina [1 ]
机构
[1] Integrated Med Ltd, Topfield House,Ermine St, Cambridge CB23 3PQ, England
来源
JOURNAL OF PERSONALIZED MEDICINE | 2012年 / 2卷 / 04期
关键词
stratified medicines; economic value; health outcomes; multiple stakeholders; companion diagnostic; regulation; reimbursement;
D O I
10.3390/jpm2040257
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The twin forces of payors seeking fair pricing and the rising costs of developing new medicines has driven a closer relationship between pharmaceutical companies and diagnostics companies, because stratified medicines, guided by companion diagnostics, offer better commercial, as well as clinical, outcomes. Stratified medicines have created clinical success and provided rapid product approvals, particularly in oncology, and indeed have changed the dynamic between drug and diagnostic developers. The commercial payback for such partnerships offered by stratified medicines has been less well articulated, but this has shifted as the benefits in risk management, pricing and value creation for all stakeholders become clearer. In this larger healthcare setting, stratified medicine provides both physicians and patients with greater insight on the disease and provides rationale for providers to understand cost-effectiveness of treatment. This article considers how the economic value of stratified medicine relationships can be recognized and translated into better outcomes for all healthcare stakeholders.
引用
收藏
页码:257 / 266
页数:10
相关论文
共 33 条
[1]  
Agarwal A, OV OPP
[2]  
Allen D., NEW SCI PERSONALIZED
[3]   The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers [J].
Atherly, A. J. ;
Camidge, D. R. .
BRITISH JOURNAL OF CANCER, 2012, 106 (06) :1100-1106
[4]  
Blair E. D, 2009, DRUG DISCOV WORLD, V22, P27
[5]   Assessing the Value-Adding Impact of Diagnostic-Type Tests on Drug Development and Marketing [J].
Blair, Edward D. .
MOLECULAR DIAGNOSIS & THERAPY, 2008, 12 (05) :331-337
[6]   Drug-diagnostic co-development: how to harness the value [J].
Blair, Edward D. ;
Blakemore, James A. .
DRUG DISCOVERY TODAY, 2011, 16 (19-20) :902-905
[7]   Molecular diagnostics and personalized medicine: value-assessed opportunities for multiple stakeholders [J].
Blair, Edward D. .
PERSONALIZED MEDICINE, 2010, 7 (02) :143-161
[8]   Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). [J].
Camidge, D. R. ;
Bang, Y. ;
Kwak, E. L. ;
Shaw, A. T. ;
Iafrate, A. J. ;
Maki, R. G. ;
Solomon, B. J. ;
Ou, S. I. ;
Salgia, R. ;
Wilner, K. D. ;
Costa, D. B. ;
Shapiro, G. ;
LoRusso, P. ;
Stephenson, P. ;
Tang, Y. ;
Ruffner, K. ;
Clark, J. W. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[9]   Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].
Chapman, Paul B. ;
Hauschild, Axel ;
Robert, Caroline ;
Haanen, John B. ;
Ascierto, Paolo ;
Larkin, James ;
Dummer, Reinhard ;
Garbe, Claus ;
Testori, Alessandro ;
Maio, Michele ;
Hogg, David ;
Lorigan, Paul ;
Lebbe, Celeste ;
Jouary, Thomas ;
Schadendorf, Dirk ;
Ribas, Antoni ;
O'Day, Steven J. ;
Sosman, Jeffrey A. ;
Kirkwood, John M. ;
Eggermont, Alexander M. M. ;
Dreno, Brigitte ;
Nolop, Keith ;
Li, Jiang ;
Nelson, Betty ;
Hou, Jeannie ;
Lee, Richard J. ;
Flaherty, Keith T. ;
McArthur, Grant A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516
[10]   Co-development of a companion diagnostic for targeted cancer therapy [J].
Cheng, Suzanne ;
Koch, Walter H. ;
Wu, Lin .
NEW BIOTECHNOLOGY, 2012, 29 (06) :682-688